Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyradiotherapyRegional therapyVisceral SurgeryDiseaseColon CancerEsophageal CancerGastric CancerPeritoneal Carcinomatosis, SecondarySubgroupAdenocarcinomaAdenocarcinoma of the esophagogastric junction (AEG)CLDN18.2 positive and HER2 negativeHER2+Mismatch Repair - deficient / Microsatellite Instability - high (dMMR/MSI-H)PD-L1 with CPS from 10PD-L1+Squamous Cell CarcinomaunfitICD10C15.-C16.-C16.0C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C78.6MeSHEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaStomach NeoplasmsSequenceARMANI: CAPOX (CAPE1000/OXAL130), AEG/Gastric Ca (PID2933) or mFOLFOX-6 (OXAL85/CFOL400/FU2400), AEG/Gastric Ca (PID2939) -|- RAMU8/PACL80, AEG/Gastric Ca (PID327)CAPOX (CAPE1000/OXAL130), AEG/Gastric Ca, adj., A (PID689) -|- B (PID684) -|- C (PID689)CGOG1001 : TRAS8/OXAL130/CAPE1000, AEG/Gastric Ca, C1 (PID1258) -|- C2-6 (PID1301) -|- C7+ (PID1302)CheckMate-032: NIVO1/IPIL3, AEG/Gastric Ca (PID1492) -|- NIVO240 maint. (PID1493)CheckMate 577: NIVO240, Esophageal Ca/AEG, adj., C1-8 (PID1764) -|- NIVO480, C9-16 (PID1765)CheckMate 648: NIVO240/CISP80/FU800, Esophageal Ca (PID1985) -|- NIVO240, Maint. (PID1986)CheckMate 649: mFOLFOX-6 (OXAL85/LCVR400/FU2400)/NIVO240, Esophageal Ca/AEG/Gastric Ca (PID1905) -|- NIVO240 maint.,(PID1910)CheckMate 649: NIVO360/CAPE1000/OXAL130, Esophageal Ca/AEG/Gastric Ca (PID1906) -|- NIVO360 Maint. (PID1911)CISP75/TEGA25, AEG/Gastric Ca (PID202) -|- TEGA25 maint. (PID1106)DANTE/IKF-s633: ATEZ840/FLOT (DOCE50/OXAL85/CFOL200/FU2600), AEG/Gastric Ca, perioperative, C1-4.5-8 (PID2563) -|- C1-4.5-8 (PID2563) -|- ATEZ1200, C9-17 (PID2564)DOCE50/OXAL100/TEGA40, AEG/Gastric Ca, neoadj. (PID2038) -|- TEGA25, adj. (PID606)DOCE75/CISP75, Esophageal Ca/AEG, neoadj., A (PID1402) -|- DOCE20/CISP25/Radiation, B (PID1403)FU425/CFOL/20/Radiation, AEG/Gastric Ca, adj., A (PID697) -|- B (PID698) -|- C (PID697).GERCOR NEONIPIGA: NIVO240/IPIL1, AEG/Gastric Ca, perioperative, cycle 1-2 (PID2244) -|- NIVO480, cycle 3-11 (PID2245)GLOW: CAPOX(CAPE1000/OXAL130)/ZOLB800, AEG/Gastric Ca, C1 (PID2733) -|- C2-8 (PID2734) -|- Gastric Ca. (PID2735)JUPITER-06: TORI240/CISP75/PACL175, Esophagal Ca (PID3016) -|- TORI240, maint. (PID3017)KEYNOTE-059: PEMB200/CISP80/FU800, AEG/Gastric Ca (PID1451) -|- PEMB200/FU800 maint. (PID1507)KEYNOTE-585 (FLOT/PEMB)KEYNOTE-585: PEMB200/CISP80/CAPE1000, AEG/Gastric Ca, perioperative, C1-6 (PID2236) -|- PEMB200, C7-17 (PID2237).KEYNOTE-590: PEMB200/CISP80/FU800, Esophageal Ca/AEG (PID1822) -|- PEMB200/FU800 maint. (PID1823)LEAP-015: mFOLFOX-6 (OXAL85/CFOL350/FU2400)/PEMB400/LENV8, AEG/Gastric Ca, C1-2 (PID2947) or CAPOX (CAPE1000/OXAL130)/PEMB400/LENV8, AEG/Gastric Ca, C1-2 (PID2948) -|- PEMB400/LENV20, C3-18 (PID2949)MATTERHORN: DURV1500/FLOT (DOCE50/OXAL85/CFOL200/FU2600), AEG/Gastric Ca, perioperative, C1-4 (PID2952) -|- DURV1500, C5-14 (PID2953)mFOLFOX-6 (OXAL85/CFOL400/FU2400)/NIVO240/TRAS6, Esophagus Ca/AEG/Gastric Ca, C1 (PID2421) -|- C2+ (PID2422).PEMB200/TRAS8/CISP80/FU800, AEG/Gastric Ca, C1 (PID2101) -|- PEMB200/TRAS6/CISP80/FU800, C2+ (PID2102)PEMB200/TRAS8/OXAL130/CAPE1000, AEG/Gastric Ca, C1 (PID2093) -|- PEMB200/TRAS6/OXAL130/CAPE1000, C2+ (PID2094)RAMONA: NIVO240, Esophageal Ca, cycle 1-3 (PID2150) -|- NIVO240/IPIL1, cycle 4+ (PID2151)RATIONALE-305: CAPOX (CAPE1000/OXAL130), AEG/Gastric Ca (PID2933) -|- CAPOX (CAPE1000/OXAL130) - CAPE1000, Erh. (PID2934)RATIONALE-305: TISL200/CISP80/FU800, AEG/Gastric Ca (PID2937) -|- TISL200, maint. (PID2938) or TISL400, maint. (PID3063)RATIONALE-305: TISL200/OXAL130/CAPE1000, AEG/Gastric Ca (PID2935) -|- TISL200/CAPE1000, maint. (PID2936) or TISL400/CAPE1000, maint. (PID3062) -|- TISL200, maint. (PID2938) or TISL400, maint. (PID3063)RATIONALE-306: TISL200/CISP80/CAPE1000, Esophagal Ca (PID2618) -|- TISL200, maint. (PID2617) or TISL400, maint. (PID3055)RATIONALE-306: TISL200/CISP80/CAPE1000, Esophagal Ca (PID2618) -|- TISL200/CAPE1000, maint. (PID2619) or TISL400/CAPE1000, maint. (PID3061)-|- TISL200, maint. (PID2617) or TISL400, maint. (PID3055)RATIONALE-306: TISL200/CISP80/FU800, Esophagal Ca (PID2615) -|- TISL200, maint. (PID2617) or TISL400, maint. (PID3055)RATIONALE-306: TISL200/CISP80/FU800, Esophagal Ca (PID2615) -|- TISL200/FU800, maint. (PID2616) -|- TISL200, maint. (PID2617) or TISL400, maint. (PID3055)RATIONALE-306: TISL200/CISP80/PACL175, Esophageal Ca (PID2622) -|- TISL200/PACL175, maint. (PID2623) -|- TISL200, maint. (PID2617) or TISL400, maint. (PID3055)RATIONALE-306: TISL200/OXAL130/CAPE1000, Esophageal Ca (PID2621) -|- TISL200, maint. (PID2617) or TISL400, maint. (PID3055)RATIONALE-306: TISL200/OXAL130/CAPE1000, Esophageal Ca (PID2621) -|- TISL200/CAPE1000, maint. (PID2619) or TISL400/CAPE1000, maint. (PID3061) -|- TISL200, maint. (PID2617) or TISL400, maint. (PID3055)RATIONALE-306: TISL200/OXAL130/FU800, Esophagal Ca (PID2620) -|- TISL200/FU800, maint. (PID2616) -|- TISL200, maint. (PID2617) or TISL400, maint. (PID3055)RATIONALE-306: TISL200/OXAL130/FU800, Esophageal Ca (PID2620) -|- TISL200, maint. (PID2617) or TISL400, maint. (PID3055)RATIONALE-306: TISL200/OXAL130/PACL175, Esophageal Ca (PID2940) -|- TISL200/PACL175, maint. (PID 2623) -|- TISL200, maint. (PID2617) or TISL400, maint. (PID3055)SPOTLIGHTTRAS6/FLOT (DOCE50/OXAL85/CFOL200/FU2600), AEG/Gastric Ca, perioperative, C1,5 (PID2034) -|- C2-4,6-8 (PID2035) -|- C9-17 (PID2036)TRAS8/CISP80/CAPE1000, AEG/Gastric Ca, C1 (PID221) -|- C2+ (PID220) -|- Maint. (PID222)TRAS8/CISP80/FU800, AEG/Gastric Ca, C1 (PID219) -|- C2+ (PID140) -|- maint. (PID222)Antineoplastic therapySubstanceAfliberceptAtezolizumabAvelumabCapecitabineCarboplatinCisplatinDocetaxelDurvalumabEpirubicinFluorouracilFolinic acidIpilimumabIrinotecanLenvatinibNivolumabOxaliplatinPaclitaxelPembrolizumabRamucirumabRegorafenibTegafurTislelizumabToripalimabTrastuzumabTrastuzumab DeruxtecanTremelimumabTrifluridineVinorelbineZolbetuximabSubstanceAfliberceptAtezolizumabAvelumabCapecitabineCarboplatinCisplatinDocetaxelDurvalumabEpirubicinFluorouracilFolinic acidIpilimumabIrinotecanLenvatinibNivolumabOxaliplatinPaclitaxelPembrolizumabRamucirumabRegorafenibTegafurTislelizumabToripalimabTrastuzumabTrastuzumab DeruxtecanTremelimumabTrifluridineVinorelbineZolbetuximabSubstanceAfliberceptAtezolizumabAvelumabCapecitabineCarboplatinCisplatinDocetaxelDurvalumabEpirubicinFluorouracilFolinic acidIpilimumabIrinotecanLenvatinibNivolumabOxaliplatinPaclitaxelPembrolizumabRamucirumabRegorafenibTegafurTislelizumabToripalimabTrastuzumabTrastuzumab DeruxtecanTremelimumabTrifluridineVinorelbineZolbetuximabSubstanceAfliberceptAtezolizumabAvelumabCapecitabineCarboplatinCisplatinDocetaxelDurvalumabEpirubicinFluorouracilFolinic acidIpilimumabIrinotecanLenvatinibNivolumabOxaliplatinPaclitaxelPembrolizumabRamucirumabRegorafenibTegafurTislelizumabToripalimabTrastuzumabTrastuzumab DeruxtecanTremelimumabTrifluridineVinorelbineZolbetuximabAnzahl Substanzen12345 RadiotherapySupportive therapySubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%PegfilgrastimPotassium chlorideSodium ThiosulfateSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%PegfilgrastimPotassium chlorideSodium ThiosulfateSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%PegfilgrastimPotassium chlorideSodium ThiosulfateSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%PegfilgrastimPotassium chlorideSodium ThiosulfateAnzahl Substanzen123456789Protocol classificationTherapy classificationalternativecurrent standardIntensityLow doseStandard doseTherapy indicationFirst lineRefractory diseaseSecond lineseveral possibleThird line Therapy phaseInductionintraoperativMaintenanceneoadjuvantneoadjuvant / adjuvantseveral possibleTherapy intentioncurativecurative or palliativepalliativeRisksAbdominal PainAcute Kidney InjuryAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaArthalgiaAstheniaBleedingCardiotoxicityCholinergic SyndromeColitisConstipationDiarrheaDysphagiaEdemaElectrolyte DisturbanceEmbolismEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)EsophagitisFatigueFebrile NeutropeniaFistulasGastrointestinal ToxicityHand-Foot SyndromeHemorrhageHepatotoxicityHyperbilirubinemiaHyperglycemiaHyperkalemiaHypertensionHyperthyroidismHypoalbuminemiaHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypophysitisHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisNephritisNeuropathyNeurotoxicityNeutropeniaOral MucositisPainPancreatitisPleural EffusionPneumoniaPneumonitisProteinuriaPruritusPyrexiaRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic EventVomiting only studiesPublicationAuthorAjani JAAl-Batran SAl-Batran SEAndre TBang YBang YJBleiberg HCats ACenter for Esophageal and Gastric Cancer, Dana-Farber/Brigham and Women’s Cancer Center, Boston, ZAMEGA trialConroy TCunningham Dde Man FM Di Lauro LDoki YEbert MPFuchs CFuchs CSFukuoka SGong JGötze THall PSHerskovic AHoeppner JHofheinz RDHulshof MCCMIlson DHJanjigian YJanjigian YYKang YKato KKelly RJKöhne CHLee JLLorenzen SLorenzen S Lv JM. DankMacDonald JSMamdani H Minashi KMoehler MQiu MZQiu MZ Raimondi A Rha SYRuhstaller TShah MShah MAShen LShitara KStein ATepper JThuss-Patience Pvan HagenWang ZXWilke HXu JYang HYchou MDiseaseAdeno-Ca des Magens oder des ösophagogastr. Überganges (Siewert II-III), cM0, MSI, EBV negativ, ECOG 0-1Adeno-Ca des Magens oder des ösophagogastr. Überganges, cT2 und höher oder cN+, M0Adeno-Ca des Magens oder des ösophagogastr. Überganges, HER2-positiv, cT2 und höher und/oder cN+, M0, ECOG 0-2Adeno-Ca des Magens oder des ösophagogastr. Überganges, mind. cT2 und/oder cN+, ECOG 0-1Adeno-Ca des Magens oder des ösophagogastr. Überganges, Stadium II, III, oder IVA, ECOG 0-1Adeno-Ca des Magens oder des ösophagogastr. Überganges, Stadium II, III, oder IV A, ECOG 0-1Adeno-Ca des Magens oder des ösophagogastr. Überganges, Stadium II-IVA, ECOG 0-1Adeno- oder Plattenepithelkarzinom des Ösophagus, lokal fortgeschritten, nicht resektabelAdenokarzinom des gastroösophagealen Übergangs oder des Magens, dMMR/MSI-H, cT2-4cN0/+cM0Adenokarzinom des Magens oder gastroösophagealen Übergangs nach R0 Resektion, Stadium Ib-IV, ECOG 0-1Adenokarzinom ösophagogastraler Übergang und Magen, HER2+, ECOG 0-2Adenokarzinom ösophagogastraler Übergang und Magen, Her2-, CLDN18.2+, metastasiert oder inoperabel, ECOG 0-1Adenokarzinom ösophagogastraler Übergang und Magen, lokal fortgeschritten, inoperabel, oder metastasiert, ECOG 0-1Adenokarzinom ösophagogastraler Übergang und Magen, metastasiert, Erstlinie, ECOG 0-1AEG- oder Magenkarzinom, Adenokarzinom, Stadium II/III, ECOG 0-1AEG-Tumor und Magen-Ca (Adenokarzinom), metastasiert, Erstlinie, ECOG 0-2AEG/Magenkarzinom lokal fortschritten, inoperabel, mindestens 1 platinhaltige VortherapieChemonaive Patienten mit metastasiertem Magenkarzinomfortgeschrittenes Adenokarzinom des Magens/ösophagealen Übergangs, resezierbar, ECOG 0-1Fortgeschrittenes oder metastasiertes Adeno-Ca des Magens, des gastroösophagealen Übergangs oder des Ösophagus, HER2-negativ, ECOG 0-1fortgeschrittenes oder metastasiertes AEG, Magen- oder kolorektales Karzinom, refraktär oder intolerant, ECOG 0-1Fortgeschrittenes oder metastasiertes Karzinom des Ösophagus, gastroösophagealen Übergangs oder des Magens, Erstlinie, unfit Fortgeschrittenes oder metastasiertes Plattenepithelkarzinom des Ösophagus, Progress nach Erstlinientherapie, ECOG 0-1Fortgeschrittenes oder metastasiertes Plattenepithelkarzinom des Ösophagus, unabhängig von PD-L1 StatusFortgeschrittenes oder metastasiertes Plattenepithelkarzinom des Ösophagus, unabhängig von PD-L1 Status, ECOG 0-1Fortgeschrittenes oder metastasiertes Plattenepithelkarzinom des Ösophagus, unabhängig von PD-L1 Status, Progress nach Erstlinientherapie, über 65 JahreLokal fortgeschrittenes oder metastasiertes Karzinom des Ösophagus, PD-L1 CPS ≥10Lokal fortgeschrittenes oder metastasiertes Plattenepithelkarzinom des ÖsophagusLokalisiertes oder lokal fortgeschrittenes Magen-Ca oder Karzinom des gastroösopagealen Übergangs Typ II/IIIMagenkarzinom, Stadium IB– IVA, perioperativ, ECOG 0-1Met. oder fortgeschr. Magen-Ca und Adeno-Ca des ösophagogastr. Überganges, Progress nach platinbasierter Erstlinientherapie, ECOG 0-1Met. oder fortgeschr. Magen-Ca und Adeno-Ca des ösophagogastr. Überganges, Zweitlinie, Progress innerhalb 4 Monaten nach Erstlinie, ECOG 0-1Met. oder fortgeschr. Magen-Ca und Adeno-Ca des ösophagogastr. Überganges, Zweitlinie, Progress innerhalb 4/6 Monaten nach Erstchemo (adj. oder palliativ), ECOG 0-1Metastasiertes, nicht resektierbares Karzinom des gastroösophagealen Übergangs oder des Magens, ECOG 0-2Metastasiertes, oder nicht resektables Karzinom des gastroösophagealen Übergangs oder des Magens, Her2+, mind. 2 Vortherapien inkl. Trastuzumab-Vortherapie, ECOG 0-1metastasiertes Adeno-Ca des Magens und AEGmetastasiertes Adeno-Ca des Ösophagus, des gastralen Übergangs oder des Magens, ECOG 0-2Metastasiertes Adenokarzinom des Magens oder des gastroösophagealen Übergangs, ECOG 0-1, ErstlinientherapieMetastasiertes Adenokarzinom des Magens oder des gastroösophagealen Übergangs, ECOG 0-2, ErstlinientherapieMetastasiertes Adenokarzinom des Magens oder des gastroösophagealen Übergangs, Her2-, metastasiert oder nicht resektabel, ECOG 0-1Metastasiertes Adenokarzinom des Magens oder des ösophagogastralen ÜbergangsMetastasiertes Adenokarzinom Karzinom des Ösophagus, ösophago-gastralen Übergangs oder Magens; Zweitlinie nach Kombination von Fluoropyrimidin mit CisplatinMetastasiertes AEG und Magenkarzinom, mindestens 2 Vorberhandlungen, PD-L1+Metastasiertes gastroösophageales Adeno-Ca.metastasiertes gastroösophageales Adeno-Ca.Metastasiertes gastroösophageales AdenokarzinomMetastasiertes Plattenepithelkarzinom des ÖsophagusNeoadjuvante Chemotherapie bei resektablem Adenokarzinom des unteren Ösophagus, gastroösophagealen Übergangs oder MagensNicht-resektables Adeno- oder Plattenepithelkarzinom des Ösophagus, cT1-4 cN0-3 M0 oder M1 (supraklavikuläre Lymphknoten)nicht-resezierbares, metastasiertes Magen-/AEG-Ca (Adeno-), Zweitlinie, ECOG 0-1nicht operables, lokal fortgeschrittenes oder metastasiertes Ösophaguskarzinom, ERBB+, Erstlinie, ECOG 0-2nicht operables, lokal fortgeschrittenes oder metastasiertes Ösophaguskarzinom, HER2+, Erstlinie, ECOG 0-2nichtresektables, fortgeschrittenes oder metastasiertes Ösophaguskarzinom, Zweitlinie, ECOG 0-2nichtresektables Ösophaguskarzinom, Stadium I-IVA, ECOG 0-2nichtresezierbares fortgeschrittenes, refraktäres oder rezidiviertes Ösophaguskarzinom, ECOG 0-1nichtresezierbares fortgeschrittenes oder rezidiviertes Karzinom des gastroösophagealen Übergangs oder des Magens, Drittlinie, ECOG 0-1nichtresezierbares fortgeschrittenes oder rezidiviertes Karzinom des gastroösophagealen Übergangs oder des Magens, ECOG 0-1Patienten mit operiertem Karzinom des gastroösophagealen Übergangs oder des MagensPotentiell resektables Adeno- oder Plattenepithelkarzinom des Ösophagus.Potenziell resezierbares Plattenepithelkarzinom des Ösophagus, Karnofsky >90potenziell resezierbares Plattenepithelkarzinom des Ösophagus, Karnofsky > 90R0-reseziertes Karzinom des Ösophagus oder des gastroösophagealen Übergangs, Stadium cT1-4N1-3M0 (AJCC 7), nach neoadjuvanter Radiochemotherapie ohne pCR, adjuvantR0-reseziertes Karzinom des Ösophagus oder des gastroösophagealen Übergangs, Stadium II-III, nach neoadjuvanter Radiochemotherapie mit residuellem Tumor, adjuvantresezierbares Adenokarzinom des ösophagogastralen Übergangs Typ I und II/Ösophaguskarzinom, Erstlinie, ECOG 0-1Resezierbares Adenokarzinom des ösophagogastralen Übergangs Typ I und II/Ösophaguskarzinom, Erstlinie, ECOG 0-1rezidiviertes oder metastasiertes Adenokarzinom des Magens / gastroösophagealen Übergangs, Erstlinie, ECOG 0-1Thorakales Plattenepithelkarzinom des Ösophagus, Stadium II-IIIThorakales Ösophagus-Ca, unter 5 cm, T1b N0 M0 mit makroskopisch negativen Resektionsränder oder T1a N0 M0 mit lymphovaskulärer Invasion, nach endoskopischer Resektion, ECOG 0-1unbehandeltes fortgeschrittenes Adenokarzinom des Magens/Ösophagusunbehandeltes fortgeschrittenes Adenokarzinom des Magens/Ösophagus, ECOG 0-1Ösophaguskarzinom (Adeno-), cT1 cN+, cT2–4a cN+, oder cT2–4a cN0, ECOG 0-2Ösophaguskarzinom (Plattenepithel- und Adeno-Ca), Karnofsky Status > 60Ösophaguskarzinom sowie AEG-Tumor Siewert-Typ I/II (Plattenepithel- und Adeno-Ca), cT1-3, cNX, cM0, neu diagnostiziert, Kreatinin-Clearance mind. 50 ml/minOriginAbteilung für Onkologie/Hämatologie, Kliniken Essen-Mitte, Deutschland, RAINBOW Study Group, RAINBOW StudieAIOArbeitsgemeinschaft Internistische OnkologieAsan Medical Center, University of Ulsan College of Medicine, Seoul, Prodigy trialausgedehnte MARGIT / AIO StudieBarbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, United StatesCharite-University Medicine Berlin, Berlin, Germany, AIO-STO-0218 trialCharles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, USA, CheckMate 577Cleary JClinical Trial Promotion Department, Chiba Cancer Center, Chiba, JapanCollaborative Innovation Center of Cancer Medicine, Guangzhou, China, JUPITER-06 trialCROSS-Studiengruppe, Erasmus University Medical Center, Rotterdam, NLDana-Farber Cancer Institute, Harvard Medical School, Boston, USA, REGARD StudieDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, ATTRACTION-3 trialDepartment of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, HoustonDepartment of Gastrointestinal Oncology, University Cancer Hospital and Institute, BeijingDepartment of Medicine, University of MainzDepartment of Radiotherapy, Amsterdam UMC, Amsterdam, the Netherlands, ARTDECO studyDepartment of Thoracic Surgery, Sun Yatsen University Cancer Center, AME Thoracic Surgery Collaborative GroupDr. Roland Bugat, Institut Claudius Regaud, ToulouseDépartement d´Oncology Médicale, Vandoeuvre-lés-Nancy, France, PRODIGE5/ACCORD17EORTCErasmus MC Cancer Institute, Rotterdam, The NetherlandsEuropean Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative GroupFifth Medical Center, Chinese PLA General Hospital, Beijing, China, RATIONALE-306 trialFédération Nationale des Centres de Lutte Contre le Cancer, Fédération Francophone de Cancérologie DigestiveGerman Esophageal Cancer Study Group, AGMT, FFCD/FRENCH, SAKK 75/08 trialHeidelberg University, Mannheim, Germany, RAMONA trialHematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany, AIO IntegaInstitute of Clinical Cancer Research, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, GermanyIstituto Nazionale Tumori IRCCS Milan, Milan, Italy, INFINITY study by GONOKeynote-059Klinikum rechts der Isar, Klinik für Innere Medizin III, Technische Universität München, Munich, Germany, DANTE/IKF-s633Klinikum Rechts der Isar, Technische Universität München, München, Germany, RAMIRIS StudyM.D. Anderson Cancer Center, Houxton TXMedical School and University Medical Center Ostwestfalen-Lippe, Campus Hospital Lippe, Detmold, Germany, ESOPEC trialMemorial Sloan Kettering Cancer Center, A Study of the US Gastric Cancer ConsortiumMemorial Sloan Kettering Cancer Center, New YorkMemorial Sloan Kettering CancerCenter, NY, Checkmate-032 StudieMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, Keynote-811Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA, CheckMate 649Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, MATTERHORN trialNanjing Medical University, Nanjing, Jiangsu Province, ChinaNational Cancer Center Hospital, Tokyo, Japan, CheckMate 648 trialNational Cancer Center Hospital, Tokyo, Japan, KEYNOTE-590National Cancer Center Hospital East, Chiba, Japan, TAGSNational Cancer Center Hospital East, Kashiwa, Japan, LEAP-015 studyNational Cancer Center Hospital East, Kashiwa, Japan, REGONIVO trial, EPOC1603National Cancer Center Hospital East, Kashiwa City, Japan, SPOTLIGHT trialNational Cancer Center Hospital East, Kashiwanoha, Kashiwa, Chiba, Japan, DESTINY-Gastric01 trialNational Institutes of HealthNetherlands Cancer Institute, Amsterdam, Netherlands, CRITICS trialONO-4538-12, ATTRACTION-2Peking University Cancer Hospital and Institute, Beijing, China, RATIONALE-302 trialPREVENT - FLOT9 trial of the AIO / CAOGI / ACORegina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyResearch Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China, RATIONALE-305 trialRoyal Marsden Hospital, Surrey and London, UK, MAGIC trialSeoul National University College of MedicineSeoul National University College of Medicine, Seoul, Republic of Korea, KEYNOTE-585Seoul National University College of Medicine, TOGA StudieSeoul National University College of Medicine, ToGA studySorbonne University, Saint-Antoine Hospital, Paris, France, GERCOR NEONIPIGA studySt. Vincent´s Comprehensive Cancer Center, New YorkUniversity of Leeds, United Kingdom, GO2 trialUniversity of North Carolina School of Medicine, Chapel Hill, USA, CALGB 9781University of Ulsan College of Medicine, Seoul, KoreaUniversitätsmedizin Mannheim, Universität Heidelberg, Mannheim, GermanyWeill Cornell Medical College, New York City, NY, USA, GLOW trialYale Cancer Center, Yale School of Medicine, KEYNOTE-059Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, KEYNOTE-859 trialProtocols in Revision 140 protocols foundAtezolizumab 840 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - ATEZ1200, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, Cycle 9-17 (PID2564 V1.0)Atezolizumab 840 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, Cycle 1-4,5-8 (PID2563 V1.0)Avelumab 800 / Ramucirumab 8 / Paclitaxel 80, Adenocarcinoma Esophagogastric Junction and Stomach (PID2565 V1.0)Capecitabine 1000 / Cisplatin 80, adenocarcinoma esophagogastric junction and stomach (PID1417 V1.3)Capecitabine 1000 / Irinotecan 250, adenocarcinoma esophagogastric junction and stomach (PID1418 V1.2)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Nivolumab 360, Esophagogastric Carcinoma, Esophagogastric junction and Stomach (PID1906 V1.2)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Pembrolizumab 400 / Lenvatinib 8, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1-2 (PID2948 V1.0)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Zolbetuximab 600 - Zolbetuximab 600 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID2735 V1.0)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Zolbetuximab 600, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2-8 (PID2734 V1.0)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Zolbetuximab 800, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2733 V1.0)CAPOX (Capecitabine 375 / Oxaliplatin 78), Esophagogastric Carcinoma, Esophagus, Esophagogastric junction and Stomach (PID1794 V1.2)CAPOX (Oxaliplatin 130 / Capecitabine 1000) / TRAS 6, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2-6 (PID1301 V1.2)CAPOX (Oxaliplatin 130 / Capecitabine 1000) / Trastuzumab 8, Adenocarcinoma Esophagogastric Junction and Stomach, C1 (PID1258 V1.2)CAPOX - Capecitabine 1000 / Oxaliplatin 130 - Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID2934 V1.0)CAPOX - Capecitabine 1000 / Oxaliplatin 130, Adenocarcinoma Esophagogastric Junction and Stomach (PID2933 V1.0)CAPOX - Capecitabine 1000 / Oxaliplatin 130, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, part A+C (PID689 V1.3)CAPOX / Radiation - Capecitabine 825 / Oxaliplatin 40 / Radiation, adenocarcinoma esophagogastric junction and stomach, adjuvant, Part B (PID684 V1.4)Cisplatin 100 / Fluorouracil 1000 / Radiation, carcinoma esophagus and gastroesophageal junction, neoadjuvant (PID1519 V1.2)Cisplatin 100 / Fluorouracil 1000, Esophageal Cancer (PID135 V1.3)Cisplatin 100 / Fluorouracil 800, adenocarcinoma esophagus, esophagogastric junction and stomach (PID136 V1.3)Cisplatin 70 / Fluorouracil 700 / Radiation, Esophageal Cancer (PID1569 V1.2)Cisplatin 75 / Fluorouracil 1000 / Radiation, Esophageal Cancer (PID281 V1.2)Cisplatin 75 / Tegafur 25, adenocarcinoma esophagogastric junction and stomach (PID202 V1.2)Docetaxel 20 / Cisplatin 25 / Radiation, carcinoma esophagus and gastroesophageal junction, neoadjuvant, part B (PID1403 V1.1)Docetaxel 40 / Fluorouracil 2000 / Cisplatin 40, adenocarcinoma esophagogastric junction and stomach (PID2171 V1.0)Docetaxel 50 / Oxaliplatin 100 / Tegafur 25, Adenocarcinoma Esophagogastric Junction and Stomach, neoadjuvant (PID2038 V2.0)Docetaxel 60 / Oxaliplatin 100 / Capecitabine 500, adenocarcinoma esophagogastric junction and stomach (PID1230 V1.1)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750, adenocarcinoma esophagogastric junction and stomach (PID128 V1.4)Docetaxel 75 / Cisplatin 75, carcinoma esophagus and gastroesophageal junction, neoadjuvant, part A (PID1402 V1.2)Docetaxel 75, adenocarcinoma esophagus, esophagogastric junction, and stomach (PID134 V1.1)Durvalumab 1500 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - Durvalumab 1500, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 5-14 (PID2953 V1.0)Durvalumab 1500 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1-4 (PID2952 V1.0)Duvalumab 1500, carcinoma esophagus and gastroesophageal junction, adjuvant (PID2228 V1.0)Epirubicin 50 / Cisplatin 60 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach (PID1776 V1.3)Epirubicin 50 / Cisplatin 60 / Fluorouracil 200, Adenocarcinoma Esophagogastric Junction and Stomach, neoadjuvant/adjuvant. (PID1228 V1.2)Epirubicin 50 / Oxaliplatin 130 / Capecitabine 625, adenocarcinoma esophagogastric junction and stomach (PID1775 V1.2)FLO - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600, adenocarcinoma esophagogastric junction and stomach (PID142 V1.2)FLOT - Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600, adenocarcinoma esophagogastric junction and stomach (PID67 V1.4)FLOT - Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600, adenocarcinoma esophagogastric junction and stomach, perioperative (PID336 V1.4)FLOT - Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600, Esophageal Cancer, perioperative (PID2824 V1.0)Fluorouracil 400 / Folinic Acid 20 / Radiation, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, Part B (PID698 V1.2)Fluorouracil 425 / Folinic Acid 20, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, part A+C. (PID697 V1.2)FOLFIRI - Irinotecan 80 / Folinic Acid 500 / Fluorouracil 2000, adenocarcinoma esophagogastric junction and stomach (PID143 V1.2)FOLFIRI/RAMU - Ramucirumab 8 / Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, adenocarcinoma esophagogastric junction and stomach (PID1599 V1.0)FOLFOX (Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 1600) / Radiation, Esophageal Cancer (PID694 V1.1)HIPEC - Cisplatin 75, Adenocarcinoma Esophagogastric Junction and Stomach (PID2710 V1.1)Irinotecan 350, adenocarcinoma esophagogastric junction and stomach (PID139 V1.1)mFOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Nivolumab 240, Cancer Esophagus, Esophagogastric junction and Stomach (PID1905 V1.1)mFOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400), Adenocarcinoma Esophagogastric Junction and Stomach (PID2939 V1.0)mFOLFOX-6 - Nivolumab 240 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400 - Nivolumab 240, Cancer Esophagus, Esophagogastric junction and Stomach, maintenance (PID1910 V1.1)mFOLFOX-6 - Nivolumab 240 / Trastuzumab 4 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Cancer Esophagus, Esophagogastric junction and Stomach, Cycle 2+ (PID2422 V1.0)mFOLFOX-6 - Nivolumab 240 / Trastuzumab 6 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Cancer Esophagus, Esophagogastric junction and Stomach, Cycle 1 (PID2421 V1.0)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 350 / Fluorouracil 2400) / Pembrolizumab 400 / Lenvatinib 8, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1-2 (PID2947 V1.0)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab (800/600), Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2727 V1.0)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 400 - Zolbetuximab 400 / Folinic Acid 400 / Fluorouracil 2400, Adenocarcinoma Esophagogastric Junction and Stomach, Maintenance (PID2892 V1.1)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 400, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2-12 (PID2891 V1.1)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 600 - Zolbetuximab 600 / Folinic Acid 400 / Fluorouracil 2400, Adenocarcinoma Esophagogastric Junction and Stomach, Maintenance (PID2803 V1.1)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 600 - Zolbetuximab 600, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID2732 V1.0)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 600, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2-4 (PID2731 V1.0)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 800, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2890 V1.1)modified FOLFOX-6 - Aflibercept 4 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, carcinoma esophagus, esophagogastric junction and stomach (PID1915 V1.0)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID1493 V1.2)Nivolumab 1 / Ipilimumab 3, adenocarcinoma esophagogastric junction and stomach (PID1492 V1.2)Nivolumab 240 / Cisplatin 80 / Fluorouracil 800 - Nivolumab 240, Esophageal Cancer, maintenance (PID1986 V1.1)Nivolumab 240 / Cisplatin 80 / Fluorouracil 800, Esophageal Cancer (PID1985 V1.1)Nivolumab 240 / Ipilimumab 1 - Nivolumab 480, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 3-11 (PID2245 V1.0)Nivolumab 240 / Ipilimumab 1, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1-2 (PID2244 V1.0)Nivolumab 240 / Ipilimumab 1, Esophageal Cancer, Cycle 4+ (PID2151 V1.1)Nivolumab 240 / Regorafenib 80, Adenocarcinoma Esophagogastric junction, Gastric and Colorectal Carcinoma (PID580 V1.1)Nivolumab 240, adenocarcinoma esophagogastric junction and stomach (PID1381 V2.1)Nivolumab 240, carcinoma esophagus and gastroesophageal junction, adjuvant, cycle 1-8 (PID1764 V1.1)Nivolumab 240, Esophageal Cancer (PID572 V1.0)Nivolumab 240, Esophageal Cancer, Cycle 1-3 (PID2150 V1.0)Nivolumab 3 / Ipilimumab 1, Esophageal Cancer (PID1987 V1.2)Nivolumab 360 / Capecitabine 1000 / Oxaliplatin 130 - Nivolumab 360 maintenance, Carcinoma Esophagus, Esophagogastric Junction and Stomach (PID1911 V1.0)Nivolumab 480, carcinoma esophagus and gastroesophageal junction, adjuvant, cycle 9-16 (PID1765 V1.0)Paclitaxel 100 / Carboplatin 4, Carcinoma Esophagus and Gastroesophageal Junction, Induction (PID2312 V1.0)Paclitaxel 135 / Cisplatin 20 / Radiation, Esophageal Cancer, adjuvant (PID2242 V1.0)Paclitaxel 50 / Carboplatin 2 / Radiation, Cancer Esophagus and Gastroesophageal Junction (PID2241 V1.0)Paclitaxel 50 / Carboplatin 2 / Radiation, carcinoma esophagus and gastroesophageal junction, neoadjuvant (PID131 V1.3)Paclitaxel 80, Esophageal Cancer (PID693 V1.2)Pembrolizumab 200 / Cisplatin 80 / Capecitabine 1000 - Pembrolizumab 200, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 7-17. (PID2237 V1.0)Pembrolizumab 200 / Cisplatin 80 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1-6. (PID2236 V1.0)Pembrolizumab 200 / Cisplatin 80 / Fluorouracil 800 - Pembrolizumab 200 / Fluorouracil 800 maintenance, adenocarcinoma esophagogastric junction and stomach (PID1507 V1.1)Pembrolizumab 200 / Cisplatin 80 / Fluorouracil 800 - Pembrolizumab 200 / Fluorouracil 800 maintenance, esophageal and gastroesophageal junction carcinoma (PID1823 V1.0)Pembrolizumab 200 / Cisplatin 80 / Fluorouracil 800, adenocarcinoma esophagogastric junction and stomach (PID1451 V1.2)Pembrolizumab 200 / Cisplatin 80 / Fluorouracil 800, Carcinoma Esophagus and Gastroesophageal Junction (PID1822 V1.2)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - Pembrolizumab 200, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 7-17 (PID2235 V1.1)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1,4 (PID2232 V1.1)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 2,5 (PID2233 V1.1)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 3,6 (PID2234 V1.1)Pembrolizumab 200 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach (PID2577 V1.0)Pembrolizumab 200 / Trastuzumab 6 / Cisplatin 80 / Fluorouracil 800, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2+ (PID2102 V1.1)Pembrolizumab 200 / Trastuzumab 6 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2+ (PID2094 V1.2)Pembrolizumab 200 / Trastuzumab 8 / Cisplatin 80 / Fluorouracil 800, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2101 V1.1)Pembrolizumab 200 / Trastuzumab 8 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2093 V1.2)Pembrolizumab 200, adenocarcinoma esophagogastric junction and stomach (PID1299 V1.1)Pembrolizumab 400 / Lenvatinib 20, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 3-18 (PID2949 V1.0)Ramucirumab 8 / Paclitaxel 80, adenocarcinoma esophagogastric junction and stomach (PID327 V1.2)Ramucirumab 8, adenocarcinoma esophagogastric junction and stomach (PID328 V1.1)Tegafur 25, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID1106 V1.2)Tislelizumab 200 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID2936 V1.1)Tislelizumab 200 / Capecitabine 1000, Esophageal Cancer, maintenance (PID2619 V1.1)Tislelizumab 200 / Cisplatin 80 / Capecitabine 1000, Esophageal Cancer (PID2618 V1.1)Tislelizumab 200 / Cisplatin 80 / Fluorouracil 800, Adenocarcinoma Esophagogastric Junction and Stomach (PID2937 V1.1)Tislelizumab 200 / Cisplatin 80 / Fluorouracil 800, Esophageal Cancer (PID2615 V1.1)Tislelizumab 200 / Cisplatin 80 / Paclitaxel 175, Esophageal Cancer (PID2622 V1.1)Tislelizumab 200 / Fluorouracil 800, Esophageal Cancer, maintenance (PID2616 V1.1)Tislelizumab 200 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach (PID2935 V1.1)Tislelizumab 200 / Oxaliplatin 130 / Capecitabine 1000, Esophageal Cancer (PID2621 V1.1)Tislelizumab 200 / Oxaliplatin 130 / Fluorouracil 800, Esophageal Cancer (PID2620 V1.1)Tislelizumab 200 / Oxaliplatin 130 / Paclitaxel 175, Esophageal Cancer (PID2940 V1.1)Tislelizumab 200 / Paclitaxel 175, Esophageal Cancer, maintenance (PID2623 V1.1)Tislelizumab 200, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID2938 V1.1)Tislelizumab 200, Esophageal Cancer (PID2559 V1.1)Tislelizumab 200, Esophageal Cancer, maintenance (PID2617 V1.1)Tislelizumab 400 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID3062 V1.0)Tislelizumab 400 / Capecitabine 1000, Esophageal Cancer, maintenance (PID3061 V1.0)Tislelizumab 400, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID3063 V1.0)Tislelizumab 400, Esophageal Cancer (PID3056 V1.0)Tislelizumab 400, Esophageal Cancer, maintenance (PID3055 V1.0)Toripalimab 240 / Cisplatin 75 / Paclitaxel 175 - Toripalimab 240, Esophageal Cancer, maintenance (PID3017 V1.0)Toripalimab 240 / Cisplatin 75 / Paclitaxel 175, Esophageal Cancer (PID3016 V1.0)Trastuzumab 4 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - Trastuzumab 6, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 9-17 (PID2036 V1.1)Trastuzumab 4 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, Cycle 2-4,6-8 (PID2035 V1.2)Trastuzumab 6 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach, cycle 7+ (PID1302 V1.2)Trastuzumab 6 / Cisplatin 80 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach, cycle 2+ (PID220 V1.5)Trastuzumab 6 / Cisplatin 80 / Fluorouracil 800, adenocarcinoma esophagogastric junction and stomach, cycle 2+ (PID140 V1.3)Trastuzumab 6 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1.5 (PID2034 V1.1)Trastuzumab 6, maintenance, adenocarcinoma esophagogastric junction and stomach (PID222 V1.1)Trastuzumab 8 / Cisplatin 80 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach, cycle 1 (PID221 V1.5)Trastuzumab 8 / Cisplatin 80 / Fluorouracil 800, adenocarcinoma esophagogastric junction and stomach, cycle 1 (PID219 V1.3)Trastuzumab Deruxtecan 5,4, Adenocarcinoma Esophagogastric Junction and Stomach (PID1736 V1.2)Trastuzumab Deruxtecan 6.4, adenocarcinoma esophagogastric junction and stomach (PID2253 V1.0)Tremelimumab 300 / Durvalumab 1500, Adenocarcinoma Esophagogastric Junction and Stomach (PID2954 V1.0)Trifluridine 35, adenocarcinoma esophagogastric junction and stomach (PID62 V2.3)Vinorelbine 25 / Cisplatin 25 / Radiation, Esophageal Cancer, neoadjuvant (PID1384 V1.1)Vinorelbine 25 / Cisplatin 75 / Radiation, Esophageal Cancer, neoadjuvant (PID1385 V1.1)Vinorelbine 25 / Cisplatin 80, Esophageal Cancer (PID137 V1.2)Vinorelbine 25, Esophageal Cancer (PID138 V1.1)
